1 Charles Kessler European Commission Brussels FP7 2 nd call – April 2007 Health research in FP7 Innovative technologies for medicine Bialystok, 29 May.

Slides:



Advertisements
Similar presentations
1 Stéphane Hogan Head of Coordination Unit Directorate Health DG Research – European Commission Launching FP7 – Riga, 5 February 2007 The Health theme.
Advertisements

1 Albrecht Jahn, MD, PhD University of Heidelberg International European Health research in the 7 th Framework Programme with emphasis on maternal and.
Indridi Benediktsson June 2007 International Collaboration in FP7 Health Research Dr. Indridi Benediktsson Directorate Health Horizontal Aspects and Coordination.
InJoy&Train FAFB Information Day 16 November, 2007 FP7 OVERVIEW TIGRAN ARZUMANYAN.
European Framework Programme for Business FP7 UK Technology Strategy Board Driving Innovation FP7UK Opportunities in FP 7 The Health research theme Biomed.
EU support for Health Research: from FP6 to FP7
AVV February 2005 Support of the European Union to Research on Rare Diseases Dr Alain Vanvossel European Commission Research Directorate General Health.
Prof. Vincent Rollet, Taiwan Health NCP Info Day, National Cheng Kung University 06 July 2012, Tainan, Taiwan EU FP7 at Glance & 2013 Health Working Program.
Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.
Combating major diseases Gender aspects in research Gender aspects in research have a particular relevance to this theme as risk factors, biological mechanisms,
Implementation of health research funding under H2020 SC 1- “Health, demographic change and wellbeing “ Elmar Nimmesgern PhD DG Research and Innovation.
1 Biomedical Sciences Public and Environmental Health Regenerative Medicine Translational Research.
International Collaboration in FP7 Health Research
21 October 2005 CNRS Building the Europe of Knowledge Octavi Quintana Trias, Director, European Commission Health Research Directorate, DG Research, Health.
1 International dimension of the European Research Framework Programme INCO NCP Meeting, Athens, 9 June 2010 Robert Burmanjer Head of Unit DG Research.
Companies and the Sixth Framework Programme. Agenda Overview of the 6 th Framework Programme (FP6) Why participate ? Industry participation in FP6 What’s.
EoI assesment and presentation NCP 24 October 2002 Confronting the major communicable diseases linked to poverty Health Directorate F3 unit: Poverty related.
The Work of WHO in the South-East Asia Region The Work of WHO in the South-East Asia Region Biennial Report of the Regional Director 1 January
Title of Presentation 1 EU-ASEAN S&T cooperation to jointly tackle societal challenges Opportunities for future EU-ASEAN collaborations.
EU-Russia Science & Technology Cooperation under FP7 Vladimir MAYER Director Moscow Regional Office (Russia&NIS) French National Centre for Scientific.
FORESIGHT STUDY Future Trends and Challenges in Pathogenomics JUDITH SIMON & SVEN POMPE PROGRAMME GROUP MUT.
European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 Towards the Sixth Framework Programme Parallel Forum V 26 September 2002 Public.
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
SMEsgoHealth&Match2BioSME International Training&Workshop - September 13, 2007, Riga Health Theme in FP7 Dr. Uldis Berkis NCP Latvia Research areas in.
FP7 Health Work Programme MALTA 25 September 2008 Joana Namorado Horizontal Aspects & Coordination Directorate Health - Ethics/Gender DG Research – European.
1 Directorate Health DG Research – European Commission FP7 2 nd call – April 2007 The Health theme in the Cooperation programme.
Horizon 2020 The EU Framework Programme for Research and Innovation Health, Demographic Change and Wellbeing Lul Raka, NCP for Horizon 2020 – Health.
Director, DG RTD, Directorate International Cooperation
The Health theme in the Cooperation programme
Where to focus? Horizon 2020 'Health, demographic change and wellbeing' Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels,
The Innovative Medicines Initiative (IMI) High level the IMI Concept, Strategic Research Agenda and Call topics Eva Lindgren.
1 EU-funded health research activities against TB: FP6 actions and perspectives toward FP7 DG Research - European Commission 22 MARCH 2007.
September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD: a public health approach to innovation Hans V. Hogerzeil Director, Medicines Policy and Standards WHO, Geneva.
Daniel Descoutures European Commission
International Collaboration in FP7 Health Research.
Clinical trials in Framework programme 7 (FP7) EU Judita Kinkorová 2. Národní konference o doporučených postupech, Olomouc 13. listopadu 2010.
Building the Europe of Knowledge Proposals for the 7 th Research Framework Programme
1 SMEs – a priority for FP6 Barend Verachtert DG Research Unit B3 - Research and SMEs.
Seventh Framework Programme Theme 1 - Health Ph D.Olguta Iordache Health - NCP.
1 Dr Alfredo Aguilar Head of Unit Biotechnologies Directorate Food, Agriculture and Biotechnology Directorate-General for Research European Commission.
FP 6 International co-operation in Life Sciences and Technologies Life Sciences, Genomics and Biotechnology for Health Food Quality and Safety.
The Seventh Framework Programme for Research and Technological Development (FP7) supporting innovation Epp Tohver-Bulavs 07. November 2007, Tallinn.
Malta Council for Science and Technology Practicalities Health and Food, Agriculture, Fisheries & Biotechnology – Information Session 25 th September 2008.
Dr. Manuel ROMARÍS Poverty-related Diseases European Commission Research DG Microbicides BXL, 07 October 2005 HIV/AIDS Research in the Sixth Framework.
Annual Meeting of the ASADI – Science Academies as Partners for Improving the Impact of Policies in Africa Session V: Partnership Themes for Development.
Poznan 19 April Kwietnia 2005 Poznan FP6 The Next Calls for 2005 Technology Platforms FP7.
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
E u r o p e a n C o m m i s s i o nCommunity Research Global Change and Ecosystems EU environmental research : Part B Policy objectives  Lisbon strategy.
EU funding programmes – In support of a knowledge based society Stefan Thuis TU Dortmund
HORIZON 2020 SC1-Health, demographic change and wellbeing challenge Марина Николовска Министерство за образование и наука
China July 2004 The European Union Programmes for EU-China Cooperation in ICT.
FP7 /1 EUROPEAN COMMISSION - DG Research Building a Europe of Knowledge Towards the SeventhFrameworkProgramme
EHFG 7 October 2005 – Patient Safety & Research UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European.
Proposals and projects in FP7 Challenge 7 Information day Brussels January 2007 Coordination and Support Actions.
1 Framework Programme 7 Overview. 2 The Programmes within FP7 IDEAS European Research Counsel ERC PEOPLE Marie Curie Measures Initial Training Life-long.
GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.
Practical Aspects of Preparation FP 6 projects Senter/EG-Liaison Nationaal Contact Punt voor het 6de Kaderprogramma Sandra de Wild 11 december 2002.
The 7th Framework Programme for Research: Strategy of international cooperation activities Robert Burmanjer Head of Unit, “International Scientific Cooperation.
National Information Day Greece 23 July 2015 Funding priorities under the work plan 2015.
Richard Escritt, Director – Coordination of Community Actions DG Research, European Commission “The development of the ERA: Experiences from FP6 and reflections.
Medical and Health research in Norway – in brief Director Mari K. Nes 22 June 2006.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
Dr. Indridi Benediktsson Health Research
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
International Co-operation Concrete opportunities
Work Programme The social challenge “Health, Demographic Change and Wellbeing” Maia Okujava NCP for Health, Demographic Change and weii-being,
Call topic identification for 2019 call
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Coordination and Support Actions
Presentation transcript:

1 Charles Kessler European Commission Brussels FP7 2 nd call – April 2007 Health research in FP7 Innovative technologies for medicine Bialystok, 29 May 2007

2 The Health Theme in Framework Programme 7 Background Opportunities Content Conditions Examples Contacts

3 Collaborative research in FP7 Thematic Priorities 1.Health6.1 2.Food, agriculture, fisheries and biotechnology1.9 3.Information and communication technologies9.1 4.Nanosciences, nanotechnologies, materials and new production technologies3.5 5.Energy2.3 6.Environment (including climate change)1.9 7.Transport (including aeronautics)4.2 8.Socio-economic sciences and the humanities0.6 9.Security & 10. Space2.8 Total for collaborative research €32.4 billion

4 Collaborative research in the Health theme Main policy drivers:  Improving health of European citizens  Increasing competitiveness of European health- related industries and businesses  Addressing global health issues, including emerging epidemics Budget:  €6.1 billion over 7 years ( )

5 Why research at European level? Pooling and leveraging resources –Critical mass, leverage effect, big science Human capacity and excellence –International mobility, S&T capability, competition Better integration of European R&D –Pan-European policy challenges, coordination of national policies, comparative research, dissemination of results

6 EU Research Projects Networks (min 3 countries; average 7 partners) Competitive calls for proposals, peer review Scientific excellence Potential impact Industry/SMEs Third country partners Up to 75% funding from EU (was 50%) Special actions for mobility, SMEs, etc

7 Collaborative research in the Health theme Activities in 3 main areas: Biotechnology, generic tools & technologies for health Translating research for human health Optimising the delivery of healthcare to citizens + other actions across theme

8 First calls for the Health theme for (year 1 & 2 of FP7)  work programme published 22 December 2006  first deadline: 19 April 2007 €637 million  second deadline: 18 September 2007 €549 million

9 Funding levels in the Health theme Maximum (and minimum) funding levels for funding schemes: min. max.*  Small- or medium-scale focussed research project (FP) €3m  Large-scale integrating project (IP) €6m €12m  Coordination action (CA)  Support action (SA)  ERA-Net (for cancer topic) €2m * except where otherwise stated in work programme. Warning: this is an eligibility criteria !

10 Scope of research in the Health Theme In the Health theme, the Framework programme supports basic and applied collaborative research This includes discovery activities, translational research and early clinical trials (normally only phase I and II)

11 Special emphasis and measures for:  SMEs  Participation encouraged in all areas  Special topics for SMEs  Support actions  International Cooperation  Participation possible in all areas  Special International Cooperation Actions (SICA)  Coordination or Support actions Cross-cutting aspects for the Health theme in FP7

12 Success will depend on mobilisation of all actors Industrial Platforms Academia Private Sector Civil Society European Investment Bank RESEARCHDEVELOPMENTREGULATION DELIVERABLES FOR SOCIETY Parliament Commission Member States Ethical Bodies SMEs Clinicians International Cooperation Translation

13 Collaborative research in the Health theme 1: Biotechnology, generic tools and technologies  High-throughput research enhancing data generation, standardisation, acquisition & analysis  Detection, diagnosis and monitoring with emphasis on non-invasive or minimally invasive approaches  Predicting suitability, safety and efficacy of therapies develop and validate parameters, tools, methods and standards (mainly through IMI) and alternatives to animal testing  Innovative therapeutic approaches and interventions gene and cell therapy, regenerative medicine, immunotherapy and vaccines.

14 Topics from first calls in Biotech, tools & technologies High-throughput research 3 topics in first call (19 April 2007) 1 topic for second call (18 September 2007): SME-driven collaborative research projects for developing tools and technologies for high-throughput research (FP targeted to SMEs)

15 Topics from first calls in Biotech, tools & technologies Detection, diagnosis and monitoring 4 topics in first call (19 April 2007) 2 topics for second call (18 September 2007): Standardisation and improvement of pre-analytical procedures for in vitro diagnostics (IP) High throughput molecular diagnostics in individual patients for genetic diseases with heterogeneous clinical presentation (FP)

16 Topics from first calls in Biotech, tools & technologies Innovative therapeutic approaches and interventions 3 topics in immunotherapy in first call (19 April 2007) 6 topics for second call (18 September 2007): Gene therapy Dev. of gene therapy tools & technologies for clinical application (IP) Gene therapy tools targeting the central nervous system (FP). Regenerative medicine Stem cell lines for cell-based therapies (IP) Development of stem cell culture conditions (FP) Stem cells for kidney regeneration (FP) Scientific communication and perspectives of stem cell therapy research (CA/SA)

17 Collaborative research on the Health theme 2: Translating research for human health  Integrating biological data and processes: large-scale data gathering, systems biology  Research on the brain and related diseases, human development and ageing  Translational research in major infectious diseases to confront major threats to public health antimicrobial drug resistance, HIV/AIDS, malaria and TB, emerging epidemics, neglected infectious diseases  Translational research in other major diseases: cancer, cardiovascular disease, diabetes and obesity, rare diseases, and other chronic diseases

18 Topics from first calls in Translating research for health Integrating biological data and processes: large-scale data gathering 7 topics in first call (19 April 2007) Systems biology 4 topics in first call (19 April 2007) 4 topics for second call (18 September 2007): Multidisciplinary fundamental genomics and molecular biology approaches to study basic biological processes (FP) International activities in large scale data gathering for functional genomics (CA/SA) Preparing for the future challenges of systems biology (CA/SA) Traditional Chinese Medicine in post-genomic era (CA/SA - SICA)

19 Topics from first calls in Translating research for health Research on the Brain and related diseases: 6 topics in first call (19 April 2007) 4 topics for second call (18 September 2007): Restorative approaches for therapy of neurodegenerative diseases From mood disorders to experimental models (IP) Neuronal mechanisms of vision and related diseases (FP) Childhood and adolescent mental disorders (FP – SICA) Targeted Region: Eastern Europe and Central Asia and Western Balkans (FP)

20 Topics from first calls in Translating research for health Anti-microbial drug resistance: 6 topics for second call (18 September 2007): Novel targets for drugs against Gram negative bacteria (FP) Host-pathogen interactions in infections by Strep. pneumoniae (FP) An integrated platform for development and clinical evaluation of point-of-care diagnostic devices for microbial detection, antibiotic susceptibility and biomarkers (IP) Molecular epidemiology to control nosocomial and community spreading of highly virulent MDR strains of bacterial pathogens (FP) Health and economic cost of antimicrobial resistance (CA/SA) Conference on genetic and biochemical tools for post-genomic physiological analysis of Staphylococcus, in particular MRSA (CA/SA)

21 Topics from first calls in Translating research for health HIV/AIDS, malaria and tuberculosis (1) 6 topics in first call (19 April 2007) 8 topics for second call (18 September 2007): Network on HIV and anti-HIV drug resistance (IP) HIV and Hepatitis co-infection (CA/SA) Blocking transmission of malaria: the mosquito vector target (FP) European network for study and clinical management of TB drug resistance (IP) Support platform for the development of PRD vaccines (CA/SA) …

22 Topics from first calls in Translating research for health HIV/AIDS, malaria and tuberculosis (2) 3 SICA topics for second call (18 September 2007): Highly innovative research in HIV/AIDS, malaria & tuberculosis between Indian and European partners (FP – SICA) Coordination of European research activities with global initiatives, including Public-Private Partnerships (CA/SA – SICA) Targeted Region: ICPC Next generation of researchers for HIV/AIDS, malaria, tuberculosis and neglected infectious diseases (CA/SA – SICA) Targeted Region: ICPC ICPC: International Cooperation Partner Countries Potentially new and re-emerging epidemics 8 topics in first call (19 April 2007)

23 Topics from first calls in Translating research for health Potentially new and re-emerging epidemics 2 topics for second call (18 September 2007): Strengthening research on prediction, identification, modelling and surveillance of newly emerging infectious diseases in humans (IP) Definition of research needs and priorities in Europe in the area of Emerging Infectious Epidemics (CA/SA) Neglected infectious diseases 3 SICA topics for second call (18 September 2007): Development of new tools to control infectious due to parasites of the Trypanosomatidae family (FP – SICA) Development of Leishmania vaccine (FP – SICA) Targeted region ICPC Bioprospecting for drug leads (FP – SICA) ICPC: International Cooperation Partner Countries

24 Topics from first calls in Translating research for health Cancer 8 topics in first call (19 April 2007) 5 topics for second call (18 September 2007): Innovative combination clinical trials for multimodal cancer therapy Role of inflammation in tumour initiation and progression (IP) Epidemiology of gene-environment interactions involved in carcinogenesis (IP) Translating the hypoxic tumour microenvironment (IP) Studying cancer aetiology in Latin America (FP – SICA) Topic for special call across the theme (31 July 2007): ERA-NET on optimisation of the use of cancer registries for cancer research purposes (CA – max. €2m) (IP)

25 Topics from first calls in Translating research for health Cardiovascular disease 3 topics in first call (19 April 2007) 4 topics for second call, deadline 18 September 2007: Congenital pathologies affecting the heart (FP) Cell therapies for the treatment of heart ischemia (FP) Organ imaging in CVD (FP) Integrating pharmacogenomic approaches into the treatment of CVD (FP)

26 Topics from first calls in Translating research for health Diabetes and obesity 5 topics in first call (19 April 2007) 4 Topics for second call (18 September 2007): Nutritional signals and the development of new diabetes/obesity therapeutic agents (FP) Markers and treatment for diabetic neuropathy complications (FP) Geno- and phenotypical differentiation of type 2 subjects and monogenic subjects (FP) Use of beta cell imaging in diabetes mellitus (FP)

27 Topics from first calls in Translating research for health Rare Diseases 2 topics in first call (19 April 2007) Other chronic diseases 9 topics in first call (19 April 2007) 3 topics for second call (18 September 2007): Understanding and combating age-related muscle weakness (IP) Translational research for a treatment of urinary incontinence (FP) Early processes in pathogenesis of chronic inflammatory diseases (IP)

28 Collaborative research in the Health theme 3: Optimising the delivery of health care to citizens  Translating clinical research into clinical practice patient safety, better use of medicines, benchmarking, pharmacovigilance, etc.  Quality, efficiency and solidarity of health care systems organisational and financial aspects, health systems, etc.  Enhanced health promotion and disease prevention providing evidence of best public health measures – life styles, interventions, special focus on mental health, etc.

29 Topics from first calls Optimising the delivery of healthcare SICA topics for health system research 4 topics for second call (18 September 2007): Epidemiological investigations into long-term trends of population health as consequence of socio-economic transitions, including life- style induced health problems (FP – SICA) Targeted regions: MPC, Russia, Eastern European and Central Asia Universal and equitable access to health care and health financing. (FP – SICA). Targeted regions: MPC, ACP, Asia and Latin America Health care intervention research – optimising hospital care (FP – SICA). Targeted region: Western Balkans Health care intervention research – improving pre-natal and maternal care (FP – SICA) Targeted regions: ACP and MPC MPC: Mediterranean Partner countries ACP: African, Caribbean and Pacific countries

30 Topics from first calls across the Health Theme (Area 4.1) 7 topics in first call (19 April 2007) 1 SICA topic for second call (18 September 2007): Promotion and facilitation of international cooperation in areas relevant to the objectives of the Health Theme (CA/SA)

31 Same as for FP6 with a review foreseen for 2 nd phase of FP7 ( ) 3 areas are excluded from funding –Human reproductive cloning –Intentional germ line modification* (* Research relating to cancer of the gonads can be financed) –Creation of human embryos for research or stem cell procurement (including by means of somatic cell nuclear transfer) Ethical framework in FP7

32 Ethics in the Health theme Key issues  for humans: Informed Consent / Data Protection / Privacy  for animals: the 3Rs (Reduce, Replace, Refine)  for human embryonic stem cells, same conditions as in FP6 recommendations  When a researcher is using personal data, animals, human tissue or human subjects, the following points should be addressed  necessity / no alternative?  benefit / burden

33 Project example - CONSERT Concerted Safety and Efficiency Evaluation of Retroviral Transgenesis for Gene Therapy of Inherited Diseases –Genetic manipulation of HSC –Vector development –Safety and GMP –Clinical trials 23 partners; 10 countries €12 million; 4 years

34 Project example - EuroStemCell European Consortium for Stem Cell Research –Identification and isolation of stem cells –Control of differentiation –Neurological disease, Muscle repair, skin –Roadmap to clinic –Ethics and outreach 16 partners; 6 countries €12 million; 4 years

35 Further information Framework Programme 7: Become an evaluator: elcome NCP:

Thank you for your attention!